GlassScriptPhysician profile
Edward W Howard
NPI 1255590204
$8,114.07
in general payments reported to CMS, 2019-2025
34 companies · $1,492 in 2025
The $1,492 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,002 · 2020: $170 · 2021: $726 · 2022: $2,244 · 2023: $1,529 · 2024: $951 · 2025: $1,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,722 · Travel and Lodging: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,721.77 |
| Travel and Lodging | $250.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,524.11 | 2022-2025 | Diamondback Peripheral, Supera, Perclose Proglide |
| Abiomed | $1,298.59 | 2019-2025 | Impella |
| Cardiovascular Systems INC. | $926.30 | 2019-2023 | Diamondback Peripheral |
| Recor Medical INC | $561.63 | 2025 | Paradise Ultrasound Renal Denervation System |
| Medtronic, INC. | $462.33 | 2024-2025 | Symplicity G3 |
| Boston Scientific Corporation | $437.12 | 2021-2023 | Ekosonic |
| Novartis Pharmaceuticals Corporation | $389.98 | 2019-2025 | |
| Amgen INC. | $353.79 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $138.30 | 2019-2023 | Xarelto |
| Pfizer INC. | $137.52 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $85.40 | 2022-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $82.04 | 2019-2025 | Camzyos |
| Scpharmaceuticals INC. | $78.75 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $57.58 | 2019-2022 | |
| Amarin Pharma, INC. | $51.05 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $45.64 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Kiniksa Pharmaceuticals International, Plc | $44.59 | 2024 | Arcalyst |
| Medtronic Vascular, INC. | $41.19 | 2019 | |
| Tactile Systems Technology INC | $40.27 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $36.45 | 2019 | |
| Kestra Medical Technology Services, INC. | $33.53 | 2024 | Assure Wcd |
| Lilly USA, LLC | $31.71 | 2025 | Zepbound |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.50 | 2019 | |
| Sanofi-Aventis U.S. LLC | $29.12 | 2019 | |
| W. L. Gore & Associates, INC. | $27.92 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.92 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $22.85 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $20.66 | 2024 | Nexletol |
| Irhythm Technologies, INC. | $20.59 | 2019 | |
| Edwards Lifesciences Corporation | $17.03 | 2023 | Sapien 3 Ultra Resilia |
| Shockwave Medical, INC | $15.73 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Livanova USA, INC. | $15.68 | 2019 | |
| Chiesi USA, INC. | $14.86 | 2025 | Kengreal |
| Heartflow, INC. | $14.34 | 2023 | Ffrct |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.